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Abstract: After 40 years of clinical experience, levodopa remains the gold standard treatment 
for Parkinson’s disease (PD) despite the recent emergence of a host of new therapies. Some 
physicians are cautious when prescribing levodopa because of its association with motor com-
plications. Evidence now suggests that levodopa-associated complications are a result of deep 
troughs in delivery of levodopa to the brain caused by the short plasma half-life of conventional 
levodopa formulations (levodopa and a dopa decarboxylase inhibitor [DDCI]). Dosing strate-
gies, such as dose increases and dose fractionation, may be effective in the short term. For the 
longer-term, levodopa/carbidopa/entacapone provides pharmacokinetically optimized levodopa 
therapy that signiﬁ  cantly increases the plasma half-life and bioavailability of levodopa, provid-
ing more consistent plasma levodopa levels without deep troughs. Evidence from clinical trials 
in PD patients experiencing re-emergence of symptoms due to wearing-off has consistently 
shown that levodopa/DDCI and entacapone signiﬁ  cantly increases ON-time and affords greater 
functionality, as measured by the Uniﬁ  ed Parkinson’s Disease Rating Scale (UPDRS) with 
conventional levodopa. These trials have also shown that levodopa/DDCI and entacapone is 
generally well tolerated, with notable adverse events including worsening dyskinesia, nausea 
and diarrhea. Patients experiencing re-emergence of symptoms due to wearing-off may beneﬁ  t 
from optimized levodopa therapy with levodopa/carbidopa/entacapone.
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Introduction
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative condition 
associated with considerable morbidity and social and economic consequences. The 
prevalence of PD increases with age and, since life expectancy is rising worldwide, 
the global burden of care for the condition is likely to increase markedly over the next 
25 years. A recent study estimated that in 2005 there were over 1 million individu-
als with PD in Western Europe and the USA; this value was projected to more than 
double by 2030 with dramatic rises expected in developing eastern countries (Dorsey 
et al 2007). Therefore, there is an ever greater need to continue the development of 
effective management strategies for PD.
Historically, PD has been viewed as a motor disease with cardinal symptoms of 
resting tremor, rigidity and bradykinesia (Litvan et al 2003). In recent years there has 
been an increasing awareness of the importance of non-motor symptoms, such as mood 
and anxiety disorders, fatigue and apathy, cognitive impairments, sleep disorders and 
addictions (Chaudhuri et al 2006). These non-motor symptoms can be as debilitating 
as motor symptoms and contribute to severe disability, impaired quality of life and 
shortened life expectancy. Optimal PD management should, therefore, encompass Neuropsychiatric Disease and Treatment 2008:4(1) 40
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both dopaminergic replacement therapy, treatment of 
non-motor problems, such as coexistent dementia, depression 
and autonomic dysfunction, and physical intervention 
through exercise, nutritional advice, speech therapy and 
psychosocial support for both patient and carer. Together, 
these elements help to maintain the patient’s functional 
capacity and quality of life.
Levodopa – gold standard therapy 
for Parkinson’s disease
The choice of pharmacotherapy for PD has increased 
dramatically over the last 25 years as the understanding of 
the pathogenesis of PD has improved. Until the 1960s, drug 
treatment for PD was limited to anticholinergics, which had 
low efﬁ  cacy and a high incidence of associated gastrointestinal 
and neuropsychiatric side effects (Katzenschlager et al 
2003). The introduction of levodopa had a dramatic impact, 
signiﬁ  cantly reducing disability and mortality and increasing 
patient quality of life (Maier Hoehn 1983). Despite the 
emergence of a host of new dopaminergic therapies for PD, 
including dopamine agonists, dopamine reuptake inhibitors, 
and MAO-B inhibitors, levodopa remains the gold standard 
treatment for PD 40 years on.
A number of well-controlled, large-scale, long-term 
clinical trials have consistently demonstrated the superior 
symptomatic control of conventional levodopa formulations 
(levodopa and a dopa decarboxylase inhibitor [DDCI]) 
compared with dopamine agonists. The comparison of the 
agonist pramipexole with levodopa on motor complications 
of Parkinson’s disease (CALM-PD) trial compared treatment 
with conventional levodopa (levodopa/carbidopa, 100/25 mg) 
3 times/day with pramipexole (0.5 mg) 3 times/day (Holloway 
et al 2004). At 4-year follow-up, treatment with levodopa was 
associated with a signiﬁ  cant improvement in the total Uniﬁ  ed 
Parkinson’s Disease Rating Scale (UPDRS) score from 
baseline versus pramipexole (mean change 2 vs –3.2 points, 
respectively; treatment effect 5.9 points; p = 0.003). Similar 
results were reported in the 5-year 056 study, which compared 
the safety and efﬁ  cacy of conventional levodopa (50 mg once 
daily to 400 mg 3 times/day) with ropinirole (0.25–8 mg 
3 times/day) (Rascol et al 2000). In this study, treatment 
with levodopa was associated with a signiﬁ  cantly greater 
improvement in the UPDRS III (motor) score compared 
with ropinirole (mean change 4.8 vs 0.8 points, respectively; 
treatment effect 4.48 points; p = 0.008). There was also a 
trend towards improvement in the UPDRS II (activities of 
daily living [ADL]) with levodopa, although the difference 
between treatment groups was not signiﬁ  cant (p = 0.08).
Poorer functionality observed with dopamine agonists 
versus levodopa in the CALM-PD and 056 studies occurred 
despite the option of supplemental levodopa therapy in both 
trials. The recent pergolide-versus-L-dopa-monotherapy-
and-positron-emission-tomography (PELMOPET) study 
analyzed the efﬁ  cacy and safety of a third dopamine agonist, 
pergolide (0.75–5.0 mg/day), against conventional levodopa 
(150–1200 mg/day) using a strict monotherapy design that 
did not allow for levodopa rescue (Oertel et al 2006). At 
3-year follow-up, the mean change in total UPDRS score 
from baseline was improved by 6.4 points in the levodopa 
treatment arm, but had deteriorated by 2.1 points in the 
pergolide arm (p   0.001). It should be noted that pergolide is 
no longer available in the United States due to its association 
with an increased risk of cardiac ﬁ  brosis. Nevertheless, the 
substantial between-treatment difference in the PELMOPET 
study serves to highlight the superiority of levodopa over 
dopamine agonists in terms of symptomatic control. This may 
reﬂ  ect the fact that dopamine agonists act primarily on D2 
receptor subtypes, whereas exogenous dopamine generated 
from levodopa will act at both D1 and D2 dopamine sites.
The limitations of levodopa
Despite the demonstrated efficacy of treatment with 
levodopa, some physicians are cautious when prescribing 
the drug because of its association with the emergence 
of motor complications (Marsden and Parkes 1977). The 
ﬁ  rst randomized clinical trial of conventional levodopa 
(ELLDOPA), which was carried out relatively recently, 
showed that high doses of levodopa/DDCI are a factor 
in the development of motor complications (Fahn 2005). 
Complications can emerge as early as 5 to 6 months after 
treatment initiation with doses  600 mg/day (Fahn 2005). 
Wearing-off and dyskinesia associated with long-term 
conventional levodopa therapy can result in disability 
and have a signiﬁ  cant impact on a patient’s quality of life 
(Chapuis et al 2005). In a limited number of cases, usually 
young, severely-affected patients, motor complications can 
outweigh the functional beneﬁ  ts provided by treatment. 
Consequently, initiation of levodopa may be postponed in 
an attempt to delay the onset of these complications.
The rationale for initiating PD therapy with dopamine 
agonist monotherapy in early disease is based on a reduc-
tion in the risk of dyskinesias. Results from the levodopa-
controlled trials of dopamine agonists consistently show a 
marked reduction in the incidence of dyskinesia with agonist 
therapy. In the CALM-PD study, pramipexole treatment 
resulted in a signiﬁ  cant reduction in the risk of developing Neuropsychiatric Disease and Treatment 2008:4(1) 41
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dyskinesia (24.5% vs 54%; p   0.001) and wearing-off (47% 
vs 62.7%; p = 0.02) compared with levodopa (Holloway 
et al 2004). However, the incidence of clinically relevant 
“disabling dyskinesias” at 4 years follow-up was very low 
(4% vs 7%) and did not differ signiﬁ  cantly between the treat-
ment groups. In the 056 study, ropinirole was associated with 
a signiﬁ  cant reduction in the risk of developing dyskinesia 
compared with levodopa (p   0.001) with an incidence of 
20% vs 45% at 5 years; the rate of wearing-off was also lower 
with ropinirole (23% vs 34%) (Rascol et al 2000).
However, the lower efﬁ  cacy of the dopamine agonists 
means that the vast majority of patients eventually require 
the superior symptomatic control of supplemental levodopa. 
In the CALM-PD study, 72% of patients randomized to 
pramipexole required levodopa supplementation at 4 years 
(Holloway et al 2004). In the 056 trial, 66% of patients in the 
ropinirole arm required levodopa with a mean daily dose of 
427 mg of adjunct levodopa by 5 years (Rascol et al 2000). It 
could be argued that keeping levodopa doses at such a level 
or lower may protect against onset of motor complications. 
However, a recent post-hoc analysis of the 056 trial revealed 
that once levodopa is added to ropinirole therapy, the risk 
of developing dyskinesias is not signiﬁ  cantly different from 
that in patients initiated on levodopa therapy (Rascol et al 
2006). Therefore, while ropinirole monotherapy delays the 
onset of dyskinesia compared with conventional levodopa, 
it does not exert any protective effect against levodopa-
induced dyskinesia when used as adjunctive therapy. The 
implication of this ﬁ  nding is that ropinirole does not address 
the cause of motor complications associated with long-term 
levodopa therapy.
Deep troughs in levodopa delivery 
with conventional levodopa
Mounting evidence now suggests that levodopa-associated 
motor complications are a result of high dosage and the non-
continuous delivery of levodopa to the brain. Conventional 
levodopa/DDCI is rapidly metabolized in the periphery, 
resulting in a short plasma half-life of ~60–90 minutes (Nutt 
and Fellman 1984). In the early stages of PD, this short 
plasma half-life is discordant with the clinical effect of the 
drug, which may persist for many hours, indicating that sur-
viving dopaminergic neurons are able to store the exogenous 
dopamine generated from levodopa and so buffer variations 
in levodopa availability. However, with progression and fur-
ther neuronal degeneration, the levodopa-buffering capacity 
is lost and deep troughs in plasma levodopa levels correspond 
with deep troughs in dopamine within the striatum, resulting 
in pulsatile stimulation of striatal dopaminergic receptors 
(de la Fuente-Fernandez et al 2001). Under these circum-
stances, patients experience a predictable pattern of symp-
tom re-emergence that corresponds with these low troughs. 
Sustained pulsatile stimulation of dopaminergic receptors 
is also thought to underlie the pathogenesis of dyskinesia 
(Olanow et al 2006). Continuous enteral infusion of levodopa 
has been shown to signiﬁ  cantly increase the bioavailability 
of levodopa and prevent low troughs in plasma levodopa 
levels (Stocchi 2005). The improved plasma proﬁ  le achieved 
with infusion is associated with dramatic improvements in 
OFF-time and dyskinesia (Stocchi 2005). Such data support 
the theory that motor complications result from deﬁ  ciencies 
in the delivery of levodopa due to the poor pharmacokinetic 
proﬁ  le of conventional oral formulations.
Dosing strategies with conventional 
levodopa formulations
Because of the impracticality and considerable expense 
of enteral levodopa infusion, physicians generally rely on 
strategies designed to improve the delivery of oral levodopa 
to prevent motor complications. The standard approach is to 
alter the dosing regimen of conventional levodopa formula-
tions, either by increasing the size of each levodopa dose or 
by “fractionating” the total daily levodopa dose into smaller, 
more frequent doses. While these modiﬁ  cation strategies may 
be effective in the short term, they fail to address the issue 
of the short half-life of conventional levodopa in the long-
term, and thus repeated modiﬁ  cations to the dosing strategy 
are often required.
Increasing the amount of levodopa administered at each 
dose does not eliminate troughs in plasma levels and may lead 
to an increased incidence and severity of dyskinesia (Figure 1) 
(Stocchi 2006). Levodopa dose fractionating is similarly 
ineffective at reducing troughs in plasma levels and is often 
associated with intermittent re-emergence of symptoms due 
to suboptimal levodopa exposure (Stocchi 2006).
The inﬂ  uence of treatment adherence 
on levodopa efficacy
Dose fractionation may also exacerbate the issue of deep 
troughs in levodopa delivery with conventional formula-
tions through reduced adherence to treatment schedules. 
An observational study that analyzed treatment adherence 
by dispensing PD therapy into electronic monitoring bottles 
found that compliance with treatment regimens was low for 
PD (Grosset et al 2005). Adherence to the total dose was 
satisfactory ( 80%) in 80% of patients, while the remaining Neuropsychiatric Disease and Treatment 2008:4(1) 42
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20% of patients were found to be under-users. However, 
timing of medication was poor regardless of whether patients’ 
adherence to treatment was satisfactory or unsatisfactory, 
suggesting that erratic drug taking is the norm rather than 
the exception in PD.
Poor adherence to treatment regimens was signiﬁ  cantly 
associated with younger age, lower quality of life, higher 
depression scores and, notably, with taking more antipar-
kinsonian tablets per day (Grosset et al 2005). Therefore, 
increasing the number of daily doses by fractionation is 
likely to reduce treatment adherence. While non-adherence 
to long-acting drugs may have a lesser impact, the potency 
of levodopa combined with its short half-life is likely to 
accentuate the effect of a missed dose and create extended 
periods of sub-therapeutic levodopa levels. The pro-
posed association between non-continuous delivery of 
levodopa and treatment-associated motor complications 
suggests that dose fractionation may actually contribute to, 
rather than prevent, these problems in a subset of patients. 
Rather than adjusting the administration of conventional 
(A)
(B)
Figure 1 Plasma levodopa proﬁ  les with conventional levodopa dosing strategies. Schematic depicting plasma levodopa levels in Parkinson’s disease patients experiencing 
re-emergence of symptoms due to wearing-off achieved by (A) increasing the daily levodopa/carbidopa dose from 300 mg/day to 450 mg/day; (B) increasing the frequency 
of levodopa/carbidopa dosing from 3 times/day to 5 times/day.Neuropsychiatric Disease and Treatment 2008:4(1) 43
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levodopa formulations, the goal of oral levodopa therapy 
should be to optimize the pharmacokinetics of the drug and 
extend its duration of effect, and so provide similar beneﬁ  ts 
to those seen with enteral infusion of levodopa.
Optimizing the delivery of levodopa
Erratic absorption with controlled-
release levodopa
In recognition of the limitations of dose adjustment strategies, 
oral, controlled-release (CR) levodopa preparations were 
developed in the late 1980s to provide smoother, more 
continuous plasma levels of levodopa with fewer daily 
doses. These formulations use a degradable polymer matrix 
to retard the release of levodopa from the tablet into the gut. 
However, clinical experience with CR levodopa preparations 
has revealed erratic absorption and unpredictable plasma 
levels (Nyholm et al 2003). A signiﬁ  cant delay to ON-time 
is a common feature of CR formulations, and dose failure 
may also occur. A clinical study that evaluated the effects 
of CR levodopa/carbidopa (Sinemet CR®, Bristol-Myers 
Squibb Company, NJ, USA) compared with the conventional 
immediate-release formulation in levodopa-naïve patients 
found no relative therapeutic beneﬁ  t with twice-daily CR 
levodopa/carbidopa and no signiﬁ  cant difference in the rates 
of motor complications between the treatment groups (Koller 
et al 1999). Similarly, data from a clinical study of identical 
design evaluating CR levodopa/benserazide (Madopar 
CR®, Roche Products Ltd, Welwyn Garden City, UK) over 
5 years also indicated no relative therapeutic beneﬁ  t with CR 
levodopa (Dupont et al 1996). Currently, use of CR levodopa 




Levodopa/carbidopa/entacapone (Stalevo®, Novartis 
Pharmaceuticals Corporation, NJ, USA) is a pharmacokinetically 
optimized levodopa formulation that peripherally inhibits both 
of the main pathways of levodopa metabolism (Silver 2004). 
Compared with conventional levodopa, the pharmacokinetic 
proﬁ  le of levodopa with dual enzyme inhibition is markedly 
improved, increasing the half-life of levodopa by up to 85% 
and the bioavailability of the drug by 35% in plasma (Stalevo 
2007). In patients with PD, transferring from a conventional 
levodopa to levodopa/carbidopa/entacapone is associated with 
signiﬁ  cantly higher trough levels, reﬂ  ecting a more consistent 
levodopa plasma proﬁ  le (Figure 2) (Muller et al 2006). Positron 
emission tomography (PET) studies with a positron-emitting 
analog of levodopa (18F-6-L-dopa) reveal that levodopa/
carbidopa and entacapone significantly increases striatal 
levodopa delivery and storage by up to 50% in patients with PD, 
compared with conventional levodopa/carbidopa (Sawle et al 
1994). Therefore, the pharmacokinetic data would suggest that 
levodopa/carbidopa/entacapone may provide more consistent 
delivery of levodopa to the brain, so providing increased 
symptomatic beneﬁ  ts with fewer motor complications.
Clinical experience with levodopa/
dopa decarboxylase inhibitor 
and entacapone
Four randomized, double-blind, 6-month, Phase III clinical 
trials have evaluated the efﬁ  cacy and safety of levodopa/DDCI 
and entacapone therapy compared with levodopa/DDCI and 
placebo in PD patients with motor ﬂ  uctuations (Parkinson 
Study Group 1997; Rinne et al 1998; Poewe et al 2002; 
Brooks and Sagar 2003; Larsen et al 2003). Data from these 
trials demonstrate that the improved pharmacokinetic proﬁ  le of 
levodopa/DDCI and entacapone therapy translates into greater 
efﬁ  cacy, providing signiﬁ  cant beneﬁ  ts in terms of symptom 
control compared with conventional levodopa. In the study by 
Rinne et al, levodopa/DDCI and entacapone therapy signiﬁ  -
cantly increased the proportion of ON-time by 16% (treatment 
effect +1.4 hours vs placebo; p   0.001) and, correspond-
ingly, reduced OFF-time by 24% (treatment effect –1.3 hours 
vs placebo; p   0.001) over the 6-month treatment period 
(Stalevo 2007). This increased duration of self-reported 
symptomatic control was reﬂ  ected in functional beneﬁ  ts of 
ADL and motor control as measured by UPDRS sub-scales 
II and III, respectively (Figure 3). There were no signiﬁ  cant 
differences between treatment arms in the UPDRS I sub-scale 
(mentation, behaviour and mood). However, improvements in 
both UPDRS II and III sub-scales, and the total UPDRS score 
were signiﬁ  cantly greater with levodopa/DDCI and entacapone 
than with levodopa/DDCI and placebo (p   0.05) (Figure 3). 
These beneﬁ  ts were achieved despite a 12% reduction in 
the mean daily levodopa dose, from 701 mg at baseline to 
614 mg at 6 months. Over the same time period the mean daily 
levodopa dose increased by 2% in the control group, resulting 
in a difference of 102 mg/day between the groups at the end 
of the study (p   0.001) (Rinne et al 1998).
Levodopa/DDCI and entacapone therapy was generally 
well tolerated; the adverse events reported signiﬁ  cantly 
(p   0.05) more frequently than in the control group were 
nausea (20% vs 8%, respectively), diarrhea (20% vs 7%, Neuropsychiatric Disease and Treatment 2008:4(1) 44
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respectively), harmless discoloration of urine (11% vs 
1%, respectively) and worsening of dyskinesia (8% vs 
1%, respectively) (Rinne et al 1998). The incidence of 
disabling or painful dyskinesias was not increased and the 
dyskinesias that did occur could be effectively managed with 
dose reductions. No patients withdrew from the study due 
to dyskinesia. Similar results were achieved in the major 
trials of levodopa/DDCI and entacapone with adverse events 
summarized in Table 1 (Parkinson Study Group 1997; Rinne 
et al 1998; Myllyla et al 2001; Poewe et al 2002; Brooks and 
Sagar 2003).
Long-term follow-up of the study in a single-arm, 
open-label extension revealed that the symptomatic beneﬁ  ts 
and tolerability of levodopa/DDCI and entacapone therapy were 
maintained at 3 years (Larsen et al 2003). As in the double-blind 
phase, UPDRS II and III scores improved in the initial stages 
of treatment and remained comparable with baseline levels at 
3-year follow-up (Figure 4). These measurements, conducted 
during patients’ ON-time, indicate that levodopa/DDCI and 
entacapone maintained the quality of ON-time in PD patients 
with motor ﬂ  uctuations. Furthermore, the mean daily levodopa 
dose remained below baseline levels for the duration of the 
p
Figure 2 Plasma levodopa proﬁ  le with levodopa/carbidopa/entacapone versus levodopa/carbidopa. Treatment with levodopa/carbidopa/entacapone 3 times/day signiﬁ  cantly 
improves troughs in plasma levodopa levels compared with equivalent doses of levodopa/carbidopa in patients with Parkinson’s disease; *p   0.05; †p   0.01; ‡p   0.001; 
SEM, standard error of the mean.
Figure 3 Efﬁ  cacy of levodopa/dopa decarboxylase inhibitor and entacapone therapy in the short-term.   Treatment with levodopa/DDCI and entacapone is associated with signiﬁ  -
cant improvements in functional control as determined by UPDRS total,   ADL and motor scores compared with levodopa/DDCI and placebo over 6 months. *p   0.01; †p   0.05.
Abbreviations: UPDRS, Uniﬁ  ed Parkinson’s Disease Rating Scale;   ADL, activities of daily living; DDCI, dopa decarboxylase inhibitor.Neuropsychiatric Disease and Treatment 2008:4(1) 45
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3-year follow-up, and remained signiﬁ  cantly lower at 3 years 
versus baseline (696 vs 737 mg/day, respectively; p = 0.0034) 
(Larsen et al 2003). The most frequent adverse events reported 
in the study were insomnia (30%), dizziness (20%), nausea 
(20%) and aggravation of parkinsonian symptoms (17%). 
A total of 14% of patients discontinued treatment due to an 
adverse event, with diarrhea, hallucinations and abdominal 
pain the most frequent reasons.
When to optimize levodopa therapy
It has recently been suggested that normalization of basal 
ganglia function through earlier initiation of dopaminergic 
therapy may delay clinical progression and provide long-term 
functional beneﬁ  ts (Schapira and Obeso 2006). This theory 
is supported by data from a retrospective pooled analysis of 
three comparably designed, double-blind, Phase III studies 
(Parkinson Study Group 1997; Rinne et al 1998; Poewe et al 
2002) and their long-term, open-label extensions (Larsen et al 
2003) conducted in PD patients with motor ﬂ  uctuations on 
conventional levodopa. The analysis divided patients into two 
groups: those who received levodopa/DDCI and entacapone 
during the 6-month double-blind phase (early start), and those 
who received levodopa/DDCI and placebo in the double-blind 
phase but moved over to levodopa/DDCI and entacapone in 
the open-label extension (delayed start). At 1-year follow-up, 
patients in the early start group reported a signiﬁ  cantly greater 
improvement in the UPDRS III score (1.33 points) compared 
with patients in the delayed start group (Nissinen et al 2006). 
This study is the ﬁ  rst to indicate that earlier initiation of 
optimized levodopa therapy may have additional beneﬁ  ts for 
patients on conventional levodopa and experiencing re-emer-
gence of symptoms due to wearing-off, and that delaying such 
therapy might adversely affect long-term patient beneﬁ  t.
Efﬁ  cacy of levodopa/carbidopa/
entacapone in patients with stable 
Parkinson’s disease
Levodopa/carbidopa/entacapone is indicated for the treatment 
of patients with PD experiencing a re-emergence of their 
symptoms due to wearing-off; however, its effects have also 
been evaluated in patients with stable PD (ie non-ﬂ  uctuating 
disease) (Poewe et al 2002; Brooks and Sagar 2003). In the 
subset of stable patients included in the Celomen study group 
Figure 4 Efﬁ  cacy of levodopa/dopa decarboxylase inhibitor and entacapone therapy in the long-term. Functionality is maintained over three years with levodopa/DDCI and 
entacapone.
‡p = not signiﬁ  cant.
Abbreviations: UPDRS, Uniﬁ  ed Parkinson’s Disease Rating Scale;   ADL, activities of daily living; DDCI, dopa decarboxylase inhibitor.
Table 1 Most frequent adverse events associated with levodopa/
dopa decarboxylase inhibitor and entacapone therapy
Adverse event  Patients (%)
 Levodopa/DDCI  Levodopa/DDCI 
  and entacapone  and placebo
 (n  = 806) (n  = 497)
Dyskinesia 30.4  17.5
Nausea 13.6  7.4
Urine discoloration  10.8  0
Diarrhea 10.3  3.8
Abdominal pain  9.6  5.6
Vomiting 7.3  4.2
Constipation 7.2  4.2
Fatigue 6.1  3.6
Table based on analysis of data in the SEESAW (n = 205), NOMECOMT (n = 171), 
FILOMEN (n = 326), CELOMEN (n = 301) and UK-IRISH (n = 300) studies (Parkinson 
Study Group 1997; Rinne et al 1998; Haapaniemi et al 2001; Myllyla et al 2001; Poewe 
et al 2002; Brooks and Sagar 2003). 
Abbreviations: DDCI, dopa decarboxylase inhibitor.Neuropsychiatric Disease and Treatment 2008:4(1) 46
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(CELOMEN) trial, mean UPDRS II and III scores improved 
from baseline by 1.0 point and 2.3 points, respectively, at 
6 months with levodopa/DDCI and entacapone (Poewe et al 
2002). This is compared with a deterioration in both UPDRS 
measures with levodopa/DDCI and placebo, although the 
small sample size precluded meaningful statistical analysis 
of between-treatment differences. A similar trial designed 
to evaluate both unstable and stable patients observed no 
signiﬁ  cant improvement in mean UPDRS III motor scores 
with levodopa/DDCI and entacapone in stable patients at 
6 months. In contrast, UPDRS II ADL scores were signiﬁ  -
cantly improved in stable patients treated with levodopa/DDCI 
and entacapone compared with those receiving levodopa/
DDCI and placebo (p   0.01) (Brooks and Sagar 2003).
Increased quality of life with levodopa/
carbidopa/entacapone
It has been suggested that quality of life assessments, which 
assess all aspects of a patient’s experience of treatment, are 
a more relevant measure of a PD therapy than the range 
of rating tools currently employed (Wheatley et al 2002). 
Separate analysis of UPDRS scores and adverse events fails 
to empirically consider the competing beneﬁ  ts and risks of 
treatment. Quality of life measures may be particularly suit-
able when evaluating treatment in early PD when the extent 
of motor complications is low, which makes identiﬁ  cation 
of changes in functionality difﬁ  cult.
The recent QUEST-AP study, a randomized, double-blind, 
parallel-group design trial compared the efﬁ  cacy of levodopa/
carbidopa/entacapone with levodopa/carbidopa in patients 
with stable PD (Fung 2006). The primary efﬁ  cacy variable of 
this study was quality of life as measured by the Parkinson’s 
disease questionnaire (PDQ)-8 scale. At 12 weeks, total quality 
of life was improved with levodopa/carbidopa/entacapone but 
deteriorated with levodopa/carbidopa, with a signiﬁ  cant dif-
ference between the treatment groups (−1.4 points; p = 0.021). 
The treatment effect of levodopa/carbidopa/entacapone was 
particularly signiﬁ  cant in the emotional wellbeing, social rela-
tionships, communication and stigma aspects of the PDQ-8 
scale (Figure 5). Among secondary efﬁ  cacy variables, signiﬁ  -
cant reductions in the total and UPDRS II (ADL) scores were 
reported (p = 0.047 and p = 0.032, respectively).
Conclusions
After 40 years of clinical experience, levodopa remains the 
most effective method of managing the symptoms of PD. 
However, conventional levodopa formulations are often used 
sparingly by physicians concerned about the possibility of 
motor complications with long-term use. Regardless of initial 
treatment, the vast majority of patients with PD will eventually 
require the superior symptomatic control afforded by levodopa 
therapy. It is now widely recognized that the poor pharmacoki-
netic proﬁ  le of conventional levodopa is an important factor in 
the development of motor complications. Consequently, there 
p  0.025
p  0.037
p  0.007 p  0.033 p  0.056
Figure 5 Effect of levodopa/carbidopa/entacapone on quality of life in patients with stable Parkinson’s disease.   Treatment with levodopa/carbidopa/entacapone is associated 
with signiﬁ  cant beneﬁ  ts in terms of quality of life compared with levodopa/carbidopa, as determined by the Parkinson’s disease questionnaire-8.
Abbreviations: PDQ, Parkinson’s disease questionnaire; NS, not signiﬁ  cant; Q, question.Neuropsychiatric Disease and Treatment 2008:4(1) 47
Improved symptomatic control with levodopa/carbidopa/entacapone
is a need for optimized oral levodopa therapy that overcomes 
the limitations of conventional levodopa formulations while 
providing effective symptomatic control.
Levodopa/carbidopa/entacapone is a pharmacokinetically 
optimized levodopa formulation that offers more consistent 
plasma levodopa levels without deep troughs. Clinical evi-
dence in PD patients experiencing motor ﬂ  uctuations with 
conventional levodopa demonstrates that treatment with 
levodopa/DDCI and entacapone signiﬁ  cantly increases time 
with less symptoms and affords greater functionality, as 
measured by UPDRS and quality of life scales. These beneﬁ  ts 
are maintained for at least 3 years with no need to increase 
the mean daily levodopa dose over this period. Furthermore, 
earlier initiation of levodopa/DDCI and entacapone therapy 
may also provide functional beneﬁ  ts compared with delay-
ing treatment. Levodopa/DDCI and entacapone is generally 
well tolerated, with the most notable adverse events observed 
in clinical trials being an increased incidence of dyskinesia, 
nausea and diarrhea. Overall, these results suggest that 
patients experiencing re-emergence of symptoms due to 
wearing-off may beneﬁ  t from optimized levodopa therapy 
with levodopa/carbidopa/entacapone.
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